Abstract

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists formetastatic disease. Similarly to cutaneousmelanoma, up to 50%of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - 2019

Keywords

  • BRAF
  • conjunctival

Fingerprint

Dive into the research topics of 'Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma'. Together they form a unique fingerprint.

Cite this